(Q36373454)

13 August 2017

An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia (English)

1 reference

multicenter clinical trial

13 August 2017

0 references

0 references

1 reference

Gahan Pandina

1

1 reference

13 August 2017

Stuart Kushner

series ordinal

2

1 reference

13 August 2017

Keith Karcher

series ordinal

3

1 reference

13 August 2017

Magali Haas

series ordinal

4

1 reference

13 August 2017

7 June 2012

1 reference

Child and Adolescent Psychiatry and Mental Health

13 August 2017

1 reference

13 August 2017

6

1 reference

13 August 2017

1

1 reference

13 August 2017

23

1 reference

https://scigraph.springernature.com/pub.10.1186/1753-2000-6-23

13 August 2017

0 references

cites work

The safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: a pooled analysis of 4 clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489792

Body weight and plasma levels of ghrelin and leptin during treatment with olanzapine

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489792

Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489792

Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489792

Pre-treatment, baseline, and outcome differences between early-onset and adult-onset psychosis in an epidemiological cohort of 636 first-episode patients.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489792

Risperidone in the management of disruptive behavior disorders

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489792

Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489792

Schizophrenia and related disorders in children and adolescents.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489792

Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. American Academy of Child and Adolescent Psychiatry

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489792

Childhood-onset schizophrenia: history of the concept and recent studies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489792

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489792

Risperidone in the treatment of schizophrenia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489792

A children's global assessment scale (CGAS)

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489792

Variations in pattern of pubertal changes in girls

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489792

Variations in the Pattern of Pubertal Changes in Boys

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489792

The positive and negative syndrome scale (PANSS) for schizophrenia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489792

A rating scale for drug-induced akathisia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489792

A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489792

Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489792

The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489792

A rating scale for extrapyramidal side effects

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489792

Risperidone: clinical safety and efficacy in schizophrenia

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489792

A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia

28 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1753-2000-6-23

Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1753-2000-6-23

Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1753-2000-6-23

Olanzapine versus placebo in the treatment of adolescents with bipolar mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1753-2000-6-23

Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1753-2000-6-23

A longitudinal study on the impact of antipsychotic treatment on serum leptin in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1753-2000-6-23

Pronounced early increase in circulating leptin predicts a lower weight gain during clozapine treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1753-2000-6-23

Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1753-2000-6-23

A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1753-2000-6-23

Long-term safety and efficacy of risperidone in children with disruptive behaviour disorders. Results of a 2-year extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1753-2000-6-23

Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489792

Childhood-onset schizophrenia: a followup study.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3489792

Addressing adverse effects of antipsychotic treatment in young patients with schizophrenia

21 September 2018

1 reference

12 December 2020

A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients

1 reference

12 December 2020

Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: efficacy, safety, and tolerability

1 reference

12 December 2020

Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study

1 reference

12 December 2020

Identifiers

DOI

10.1186/1753-2000-6-23

1 reference

Dimensions Publication ID

13 August 2017

0 references

1 reference

13 August 2017

1 reference